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Introduction: Pseudophakic cystoid macular edema is a common cause of poor vision after 
cataract surgery, and topical corticosteroids and nonsteroidal anti-inflammatory drugs are used for 
its treatment. We investigated the effectiveness of difluprednate (Durezol®, recently approved by 
the US Food and Drug Administration) in the treatment of cystoid macular edema, assisted with 
spectral domain optical coherence tomography (SD-OCT).
Case report: A 63-year-old African-American woman presented 6 weeks after uneventful 
cataract surgery in her left eye with decreased vision and associated distortion of the central 
visual field. Fluorescein angiogram and SD-OCT confirmed pseudophakic cystoid macular 
edema. Difluprednate was topically administered twice daily and monitored with serial   imaging. 
Resolution was noted after 1 month of topical therapy, with improvement in visual acuity and 
resolution of distortion.
Conclusion: Difluprednate is an effective treatment for patients with severe pseudophakic 
cystoid macular edema. SD-OCT allows the physician to monitor resolution of the macular 
edema easily.
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Introduction
Cystoid macular edema (CME) is a common cause of visual loss after complicated 
cataract surgery, but may also occur in uncomplicated cases.1 Intraoperative 
vitreous loss, placement of an anterior chamber intraocular lens, and prolonged 
postoperative inflammation are some of the risk factors associated with CME.1 
Patients experience diminished vision approximately 6–8 weeks after cataract 
surgery. Diagnosis is based on clinical findings, characteristic appearance on 
fundus fluorescein angiography, and optical coherence tomography. Common 
modalities of treatment currently include topical nonsteroidal anti-inflammatory 
drugs alone or in combination with topical corticosteroids for 3–4 months or until 
resolution of the macular edema. In patients with persistent CME, intravitreal 
injections of bevacizumab or triamcinolone have been used with success.1,2 In this 
case report, we describe rapid resolution of pseudophakic CME documented with 
spectral domain optical coherence tomography (SD-OCT, Spectralis®, Heidelberg 
Engineering Inc, Carlsbad, CA) after topical administration of difluprednate 0.05% 
(Durezol®, Sirion Therapeutics, Tampa, FL), a fluorinated corticosteroid with 
reportedly greater intraocular penetration.3–6
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Case presentation
A 63-year-old African-American woman with a history 
of hypertension, asthma, gastroesophageal reflux disease, 
anemia, and hyperlipidemia, was referred for evaluation of 
poor vision. Her past ocular history was unremarkable. Her 
best corrected visual acuity was 20/30 in each eye, but on 
glare testing decreased to 20/40 in the right eye and 20/60 in 
the left eye. Near vision examination revealed J1+ in each 
eye and color vision was full. Amsler and visual fields were 
normal. Motility and pupillary examinations were normal. 
Intraocular pressures were 16 mmHg in the right eye and 
18 mmHg in the left eye. Anterior segment examination 
was notable for a nuclear sclerotic cataract in both eyes (left 
greater than right). Dilated fundus examination revealed 
minimal diabetic retinopathy with microaneurysms in the 
posterior pole.
Uneventful phacoemulsification was performed to her 
left eye and a B and L LI61AO + 21.5 diopter lens was 
placed into the capsular bag. On postoperative day 1, the 
patient’s visual acuity was 20/20 and intraocular pressure was 
16 mmHg in the left eye. A routine postoperative regimen 
of tobramycin and dexamethasone was started and tapered 
off over the next 4 weeks. Six weeks later, she presented 
with central visual field distortion and decreased vision in 
her left eye. Best corrected visual acuity in her left eye was 
20/50 + 2, with refraction of −0.50 + 0.25 × 005. Slit lamp 
examination revealed a well centered intraocular lens without 
anterior chamber inflammation. Dilated fundus examination 
revealed diffuse macular edema.
SD-OCT revealed CME with intraretinal thickening and 
a central macular thickness of 819 µm (0.64 mm3) in her 
left eye (Figure 1A and C). Fundus fluorescein angiography 
confirmed severe CME in the late phase of the angiogram 
(Figure 1B).
Although pseudophakic CME may resolve spontaneously, 
topical difluprednate was initiated in the left eye twice daily 
given the severe cystic macular thickening. After 4 weeks of 
therapy, her best corrected visual acuity improved to 20/20 in 
the left eye and the CME resolved clinically. The intraocular 
pressure remained at 16 mmHg in the left eye after 4 weeks 
of therapy. SD-OCT imaging showed complete resolution 
of CME with a central macular thickness of 310 (0.24 mm3, 
Figure 2A and C) Repeat fundus fluorescein angiography 
showed resolution of CME (Figure 2B).
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Figure 1 Spectral domain optical coherence tomography (A), fluorescein angiogram (B), and spectral domain optical coherence tomography thickness map (C) of the left 
eye prior to treatment with difluprednate.
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Discussion
Pseudophakic CME is the most common cause of unexpected 
visual loss after cataract surgery.7,8 The incidence is estimated 
to range from 4% to 11% in the modern era. Because large 
randomized controlled trials with long-term follow-up are 
lacking, no standardized treatment or prophylactic regimen 
exists.7,8 Currently, topical nonsteroidal anti-inflammatory 
drugs and topical corticosteroids are first-line treatment 
modalities. Refractory cases of CME may be treated 
intravitreally with corticosteroids, nonsteroidal anti-
inflammatory drugs, or antivascular endothelial growth factor 
agents.2,7–10 We chose to administer topical difluprednate 
in view of its effectiveness, potency, and bioavailability. 
Furthermore, topical treatment modalities avoid the risks of 
intravitreal injections which include increased intraocular 
pressure and endophthalmitis.
Difluprednate (difluoroprednisolone butyrate acetate) is 
effective in the treatment of anterior uveitis, postoperative 
inflammation, and pain. However, its efficacy in postopera-
tive CME is not described. Difluprednate, recently approved 
for inflammation and pain associated with ocular surgery 
in 2008, penetrates the corneal epithelium rapidly and 
  effectively.3 Difluoroprednisolone butyrate, its active metabo-
lite, has strong corticosteroid receptor agonist activity and 
is six times stronger than prednisolone in animal studies.3 It 
is preserved with sorbic acid that is nontoxic to the corneal 
surface compared with benzalkonium chloride.3 Fluorina-
tion at the C-6 and C-9 positions increases glucocorticoid 
receptor binding affinity and the addition of butyrate and 
acetate esters at positions C-17 and C-21 improve corneal 
penetration compared with topical betamethasone.4,5 In 
addition, difluprednate is administered in an emulsion, thus 
increasing its bioavailability.4 The dose uniformity of diflu-
prednate ophthalmic emulsion 0.05% was highly predict-
able compared with both branded and generic prednisolone 
(shaken or unshaken) acetate suspensions.6 Similar to other 
corticosteroids, difluprednate may cause a steroid-responsive 
intraocular pressure rise; however, its effect is minimal com-
pared with other drugs in its class.10
We present a patient with severe CME with a central 
macular thickness of 819 µm (0.64 mm3) and the presence 
of subretinal fluid on OCT. Although pseudophakic CME 
may spontaneously resolve, severe cystic thickening warrants 
therapy.7,8 Our patient’s visual acuity returned to normal after 
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Figure 2 Spectral domain optical coherence tomography (A), fluorescein angiogram (B), and spectral domain optical coherence tomography thickness map (C) of the left 
eye after treatment with difluprednate.
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using difluprednate for 4 weeks and the ultrastructural changes 
in the fovea resolved with recovery of normal anatomy.
Conclusion
In summary, severe pseudophakic CME resolves rapidly 
after topical administration of difluprednate. SD-OCT was 
helpful both in identifying CME and monitoring of treatment 
with serial scans.
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